The Alzheimer blood test in primary care took a clear step forward at a major scientific meeting reported in July 2026: in a large real-world study, once family doctors could see a patient’s blood biomarker result, they diagnosed Alzheimer’s disease almost as accurately as memory specialists. This is less a brand-new test than a new place to use one — the family doctor’s office, where most people with memory concerns are seen first. In this article you’ll learn what the study found, why moving an accurate diagnosis closer to home matters, what the result can and cannot tell you, and why a doctor’s assessment still comes first.
What the AAIC 2026 study found
The findings were reported for the first time at the Alzheimer’s Association International Conference (AAIC) 2026 in London. Researchers ran one of the first real-world studies of its kind, involving more than 1,300 patients and 165 physicians. Patients seen in primary care were also assessed independently by dementia specialists, which allowed a direct, head-to-head comparison of accuracy.
Before seeing any blood result, primary care physicians identified Alzheimer’s correctly about 65% of the time. After they reviewed the blood biomarker result, their accuracy rose to about 93% — close to the 94% the specialists reached on the same patients. The test used in the study, PrecivityAD2, measures amyloid beta and phosphorylated tau, two proteins tied to Alzheimer’s. The doctors did more than score better on paper: after seeing the result, they changed the diagnosis for roughly one in three primary care patients and adjusted the care plan for more than half. The study’s lead author, neurologist Sebastian Palmqvist of Lund University, described the effect as closing the gap between primary and specialty care.
Why diagnosing Alzheimer’s in primary care matters
Access is the real change here. Today, confirming Alzheimer’s usually relies on a PET brain scan or a spinal-fluid sample — accurate tools that are costly and mostly available in memory clinics. Most people, though, first raise memory worries with a family doctor, then wait weeks or months for a referral and specialist testing. A result a general practitioner can read during a routine visit shortens that path. For a reminder of what giving a sample involves, a separate guide walks through the standard blood test process.
In this study, the test was most useful in primary care for one specific job: ruling Alzheimer’s out. After a negative result, family doctors’ willingness to confidently exclude Alzheimer’s roughly doubled, which frees them to look for other, sometimes treatable causes of memory or thinking changes.
What the test actually measures
The blood test reads two proteins linked to Alzheimer’s: a form of tau called p-tau217, and a fragment of amyloid. Their balance in blood tracks the amyloid plaques that build up in the brain, so a tube of blood becomes an indirect window onto that process. This is the same biology behind the FDA-cleared Alzheimer blood test our newsroom already explains, and behind the p-tau217 test that predicts risk a decade before symptoms. To review how these proteins drive the condition, our team explains the biology of Alzheimer’s disease.
What the accuracy numbers mean
The headline is not that the test is flawless, but that it lifts an ordinary doctor’s accuracy to near-specialist levels. The table below shows the before-and-after figures reported in the interim analysis.
| Groep | Accuracy before the blood test | Accuracy after the result |
|---|---|---|
| Primary care physicians | About 65% | About 93% |
| Dementia specialists | About 74% | About 89% (94% head-to-head on primary care patients) |
Two points are worth keeping in mind. The specialists still edged ahead, and in everyday care the two groups converged near 90% only after both had the blood result in hand. And the largest practical gain in primary care was in ruling the disease out, not in making a firm diagnosis — many family doctors still preferred to send a positive result to a specialist for confirmation, which is exactly as it should be.
What a primary care blood test does not mean
The test is designed for people who already have memory or thinking symptoms and are being assessed for them. It is not a screening tool for healthy people with no symptoms, where an abnormal result is wrong far more often. A negative result is also specific to Alzheimer’s: it does not rule out every other neurological condition, so some people with a normal result will still be referred onward.
Memory and thinking changes have many causes this test does not measure — among them thyroid problems, vitamin deficiency and kidney issues. Our library explains low vitamin B12 symptoms and causes, a companion article covers normal thyroid levels, and a related guide explains the kidney function panel. Any of these can affect cognition and is worth checking before conclusions are drawn.
Wanneer moet je met een arts praten?
If you or someone close to you notices memory changes that disrupt daily life, that is the moment to raise it with a doctor, who can decide what assessment fits. Occasional forgetfulness on its own is usually part of normal aging. If testing is considered, a guide to reading your blood test results can help you follow the conversation.
Recente wetenschappelijke ontwikkelingen
According to research indexed in PubMed, the primary-care result reported in 2026 sits on top of a steady body of work.
An earlier study in JAMA (2024) tested the same idea in 1,213 people in Sweden. Family doctors’ accuracy for Alzheimer’s rose from 61% to 91% once they had the blood result, while specialists went from 73% to 91% (DOI). What this means for you: the 2026 finding is a real-world confirmation of a benefit already measured two years earlier.
A study in Nature Medicine (2025) ran a fully automated version of the test — one that works on standard laboratory machines — across 1,767 people. Accuracy was about 85% in primary care, rising to 92–94% when a two-threshold reading set aside the most uncertain results (DOI). What this means for you: the test is becoming easy for ordinary labs to run, and an “uncertain” band is built in rather than hidden.
A 2025 review in the Journal of Alzheimer’s Disease flagged one practical caveat: reduced kidney function can raise p-tau217 in the blood on its own (DOI). What this means for you: your kidney health can nudge the number, one more reason the result is read by a doctor alongside the rest of your health rather than in isolation.
Glossarium
| Termijn | Definitie |
|---|---|
| P-tau217 | A form of the tau protein, measurable in blood, that rises when Alzheimer’s-related changes are present in the brain. |
| Amyloid beta | Een proteïnefragment gemeten in een bloedtest en vergeleken met p-tau217 om amyloïde plaques te beoordelen. |
| Eerstelijnszorg | Alledaagse eerstelijnsgezondheidszorg, zoals een huisarts of algemeen arts. |
| Dementiespecialist | Een neuroloog, geriater of psychiater die zich richt op geheugen- en cognitieve stoornissen. |
| Diagnostische nauwkeurigheid | Hoe vaak een test of clinicus de juiste conclusie bereikt ten opzichte van een referentiestandaard. |
| PrecivityAD2 | De merknaam van de bloedtest die in de studie van 2026 werd gebruikt, waarbij amyloïde en p-tau worden gemeten. |
| Biomarker | Een meetbare stof in het lichaam die wijst op een normaal proces of een ziekte. |
| Uitsluiten | Een uitslag gebruiken om te bepalen dat een aandoening onwaarschijnlijk is, zodat andere oorzaken onderzocht kunnen worden. |
| Milde cognitieve stoornis | Een merkbare achteruitgang in geheugen of denkvermogen die het zelfstandig dagelijks functioneren nog niet belemmert. |
| PET-scan | Een hersenbeeldvormingstest die amyloïde plaques kan aantonen en als referentie voor bloedmarkers wordt gebruikt. |
Veelgestelde vragen
Kan mijn huisarts een bloedtest voor alzheimer aanvragen?
Steeds vaker wel, hoewel de beschikbaarheid nog per regio en kliniek verschilt. De bevindingen uit 2026 en de bijbehorende richtlijnen van de Alzheimer’s Association zijn er specifiek op gericht huisartsen te helpen deze tests goed te gebruiken. De beslissing moet worden genomen samen met een clinicus die uw klachten beoordeelt, en mag niet op verzoek worden aangevraagd, omdat de uitslag alleen zinvol is in de context van een gedegen beoordeling.
Is de bloedtest voor alzheimer nauwkeurig genoeg voor de eerstelijnszorg?
In de studie van 2026 bereikten huisartsen een nauwkeurigheid van ongeveer 93% na het zien van de uitslag, dicht bij die van specialisten bij dezelfde patiënten. Dat is sterk, maar dit cijfer weerspiegelt artsen die de test samen met het klinische beeld interpreteren, niet de test op zichzelf. Het is een hulpmiddel bij besluitvorming, geen eindoordeel.
Vervangt de bloedtest een hersenscan of ruggenprik?
Vaak vermindert het de noodzaak daarvoor, wat een groot deel van de aantrekkingskracht is, maar het vervangt ze niet automatisch. Een positieve uitslag in de eerstelijnszorg wordt vaak doorgestuurd naar een specialist ter bevestiging, en bij onduidelijke uitslagen kan alsnog een PET-scan of liquoronderzoek nodig zijn.
Wat betekent een negatieve uitslag?
Een negatieve uitslag maakt aan alzheimer gerelateerde veranderingen op het moment van testen onwaarschijnlijk, wat geruststellend is en de meest nuttige rol van de test in de eerstelijnszorg was. Het sluit echter andere aandoeningen niet uit, dus als de klachten aanhouden kan uw arts toch verder onderzoek doen of u doorverwijzen.
Is deze test bedoeld voor mensen zonder klachten?
No. It is intended for adults being evaluated for memory or thinking problems. In people with no symptoms, an abnormal result is wrong far more often, which is why current guidelines reserve the test for those already experiencing cognitive changes.
How much does the Alzheimer blood test cost?
Costs and coverage vary by location, laboratory and insurance plan. In general the price is expected to be lower than an amyloid PET scan or a spinal-fluid test, but it is worth asking your clinic and insurer what to expect before the test is ordered.
Bronnen
- Alzheimer’s Blood Test Could Bring Highly Accurate Diagnosis into Everyday Clinical Care — Alzheimer’s Association International Conference 2026 — aaic.alz.org
- FDA Clears First Blood Test Used in Diagnosing Alzheimer’s Disease — U.S. Food and Drug Administration — fda.gov
- FDA-Approved Blood Test Detects Early Markers of Alzheimer’s Disease — Johns Hopkins Medicine — hopkinsmedicine.org
- Palmqvist S, et al. — Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care — JAMA, 2024 — DOI
- Palmqvist S, et al. — Plasma phospho-tau217 for Alzheimer’s disease diagnosis in primary and secondary care using a fully automated platform — Nature Medicine, 2025 — DOI
- Arslan B, et al. — Integrating kidney function assessment into the clinical interpretation of plasma Alzheimer’s disease biomarkers — Journal of Alzheimer’s Disease, 2025 — DOI
Verder lezen
- The FDA-cleared Alzheimer blood test explained
- The p-tau217 test that predicts risk a decade early
- The biology of Alzheimer’s disease
- The many forms of dementia
- Reading your blood test results
Begrijp uw laboratoriumresultaten met AI DiagMe.
News like this is a reminder that a blood sample carries more information every year, and that lab reports are getting harder to read alone. AI DiagMe helps you understand common blood, urine and stool results in plain language: what each line measures, what an out-of-range value might point to, and which questions are worth bringing to your doctor. It is built to help you understand your results, not to diagnose you, and it never replaces a healthcare professional’s judgment.
Ontvang binnen enkele minuten een interpretatie van uw resultaten.
